Conventional clinical prognosticators of PC severity and progression include - digital rectal examination (DRE), serum prostate-specific antigen (PSA), trans-rectal ultrasound (TRUS), and TRUS-guided histopathological staging (GS)3,4. This evidence concerns the gene KLK3 and pachyonychia congenita.